Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Impact of specific high-risk human papillomavirus genotypes on survival in oropharyngeal cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Use of beta-blockers and risk of contralateral breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Low-dose aspirin use and mortality risk in patients with head and neck cancer - a nationwide cohort study of 10,770 patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Long-term exposure to air pollution and liver cancer incidence in six European cohorts

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Viral and Genomic Drivers of Squamous Cell Neoplasms Arising in the Lacrimal Drainage System

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Introduction and transmission of SARS-CoV-2 lineage B.1.1.7, Alpha variant, in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The increases observed in incidence and survival of oropharyngeal squamous cell carcinoma (OPSCC) have been attributed to human papillomavirus (HPV) infection, but the survival-impact of specific genotypes is poorly understood. We investigated the potential influence of HPV genotypes on survival in HPV-positive (HPV+) OPSCC. All patients with HPV+/p16+ OPSCC and available genotype data within the period 2011 to 2017 in Eastern Denmark were included. Descriptive statistics on clinical and tumor data, as well as overall survival (OS) and recurrence-free survival (RFS) with Cox hazard models and Kaplan-Meier plots were performed. Overall, 769 HPV+/p16+ OPSCC patients were included of which genotype HPV16 accounted for 86% (n = 662). Compared to high-risk non-HPV16 genotypes (HR non-HPV16), HPV16 patients were younger at diagnosis (median years, 60 vs 64), had a higher male to female ratio (3.7:1 vs 2.1:1), and lower performance scores of ≤1 (90%, n = 559, vs 81%, n = 74). Regarding 5-year OS and RFS, no difference was observed between HPV16 and HR non-HPV16 patients. Subgrouping the HR non-HPV16 group into HPV33 (n = 57), HPV35 (n = 26) and "other genotypes" (n = 24) a significantly worse OS in the "other genotypes" group (hazard rate: 2.33, P = .027) was shown. With similar survival results between HPV16 and non-HPV16 genotypes, genotyping in OPSCC is interesting from an epidemiological point of view as well as in vaccination programs, but not a necessary addition in prognostication of HPV+/p16+ OPSCC.

OriginalsprogEngelsk
TidsskriftInternational Journal of Cancer
Vol/bind150
Udgave nummer7
Sider (fra-til)1174-1183
Antal sider10
ISSN0020-7136
DOI
StatusUdgivet - 1 apr. 2022

Bibliografisk note

This article is protected by copyright. All rights reserved.

ID: 69825425